AYX-101: Triciribine Phosphate (TCNP) encapsulated red blood cell for autologous and/or allogeneic applications for the treatment of lung diseases. This product is backed by 5 granted US patents valid till 2034. In addition, regulatory exclusivity and novel use for rare disease (lymphangioleiomyomatosis, LAM) provide for additional IP protection.
Erycaps: Ayma recently acquired the entire IP, know-how and assets from Erytech with patent validity until 2034 in the US. This technology is fully automated and allows for preparation of AYX-101 and subsequent future products that will leverage this technology for TCNP and combination products under GMP conditions.
Arginase: As a part of Erytech acquisition, Ayma owns several patents with final expiry in certain territories in 2037. Future products containing Arginine deiminase will leverage ERYCAPS technology for automated GMP manufacturing to conduct clinical trials and subsequent development, approval and commercialization.
Exosomes/Extracellular vesicles: : This patent family is currently under examination in US and other territories and Ayma anticipates final office action in 2026-27. Exosome preparation using automated methodology will allow for exploring therapeutic opportunities in multiple indications either independently or in parternship with other companies.
